Malignant Ascites Market is Expected to Witness Significant Growth by 2036 Owing to the Launch of Novel Therapies | DelveInsight

The market dynamics for Malignant Ascites are witnessing considerable growth driven by increasing prevalence of associated cancers, rising demand for effective symptomatic therapies, and advancements in targeted and immunotherapeutic treatment approaches. Additionally, the launch of emerging therapies such as M701 (Wuhan YZY Biopharma), Catumaxomab, and others will further fuel the market.
DelveInsight, a leading market research firm, announces the release of its latest report, "DelveInsight's Malignant Ascites Market Insights, Epidemiology, and Market Forecast 2036." This comprehensive report provides an in-depth understanding of Malignant Ascites, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Malignant Ascites Market

*
The market size for Malignant Ascites in the leading markets is expected to grow significantly by 2036.

*
The United States accounted for the highest Malignant Ascites treatment market size in 7MM in 2025, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan.

*
In 2020, the total incident cases of Malignant Ascites associated cancers were 1.6 million in the 7MM.

*
Among all the associated cancers, the highest incident cases were reported in Breast Cancer. In 2020, the total incident cases of Breast Cancer were ~640,000.

*
According to Ikegami et al. (2024), Malignant Ascites accounts for about 10% of all cases of ascites and is most frequently associated with ovarian cancer, while gastric, uterine, breast, colorectal, and pancreatic cancers together account for 80% of cases.

*
According to Han & Borazanci (2023), up to 30% of patients with pancreatic ductal adenocarcinoma (PDAC) develop Malignant Ascites.

*
Leading Malignant Ascites companies, such as Wuhan YZY Biopharma, LINDIS Biotech GmbH, Pharmanovia, and others, are developing new Malignant Ascites treatment drugs that can be available in the Malignant Ascites market in the coming years.

*
The promising Malignant Ascites therapies in clinical trials include M701 and others.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/malignant-ascites-market [https://www.delveinsight.com/sample-request/malignant-ascites-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]

Key Factors Driving the Malignant Ascites Market

Increasing Prevalence of Associated Cancers: The growing incidence of ovarian, pancreatic, breast, colorectal, gastric, and liver cancers is significantly contributing to the rise in Malignant Ascites cases worldwide.

Rising Demand for Effective Symptomatic Therapies: Patients with Malignant Ascites frequently experience abdominal swelling, pain, nausea, dyspnea, and reduced appetite, creating demand for more effective therapies that improve quality of life and reduce repeated hospitalizations.

Advancements in Targeted and Immunotherapeutic Approaches: Emerging therapies including bispecific antibodies, intraperitoneal immunotherapies, and oncolytic virotherapy are expected to improve treatment outcomes and reshape the future Malignant Ascites treatment landscape.

Malignant Ascites Competitive Landscape

Several Malignant Ascites drugs in development include M701 (Wuhan YZY Biopharma), Catumaxomab, and others.

These candidates target diverse mechanisms such as EpCAM-directed bispecific antibody therapy, T-cell activation, and targeted immune-mediated tumor cell killing, aiming to improve puncture-free survival, overall survival, and symptom management in patients with Malignant Ascites.

Discover more about therapies set to grab major Malignant Ascites market share @ Malignant Ascites Treatment Landscape [https://www.delveinsight.com/sample-request/malignant-ascites-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]

Recent Developments in the Malignant Ascites Market

*
In February 2025, LINDIS Biotech GmbH and Pharmanovia announced that catumaxomab received marketing authorization from the European Commission to treat Malignant Ascites in adults with EpCAM-positive carcinomas.

*
In October 2024, Catumaxomab received a positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP).

*
In December 2025, Wuhan YZY Biopharma announced that Phase II clinical trial data for M701 demonstrated longer puncture-free survival (75 vs. 25 days) and improved overall survival compared with controls.

What is Malignant Ascites?

Malignant Ascites is the abnormal accumulation of fluid in the peritoneal cavity caused by cancer. It is commonly associated with advanced-stage malignancies such as ovarian, pancreatic, breast, colorectal, gastric, and liver cancers. Patients often experience abdominal distention, pain, nausea, shortness of breath, reduced appetite, and impaired quality of life. The pathogenesis of Malignant Ascites is multifactorial and involves increased vascular permeability, impaired lymphatic drainage, and tumor-related inflammation.

Malignant Ascites Epidemiology Segmentation

The Malignant Ascites epidemiology section provides insights into the historical and current Malignant Ascites patient pool and forecasted trends for the leading markets. The Malignant Ascites market report proffers epidemiological analysis for the study period 2022-2036 in the leading markets, segmented into:

*
Total Incident Cases of Malignant Ascites Associated Cancers

*
Total Patient Pool of Malignant Ascites

*
Indication-wise Patient Pool of Malignant Ascites

Scope of the Malignant Ascites Market Report

*
Therapeutic Assessment: Malignant Ascites current marketed and emerging therapies

*
Malignant Ascites Market Dynamics: Key Market Forecast Assumptions of Emerging Malignant Ascites Drugs and Market Outlook

*
Key Companies: Wuhan YZY Biopharma, LINDIS Biotech GmbH, Pharmanovia, and others

*
Key Therapies: M701, Catumaxomab, OK-432, KM-CART, Chemotherapy, Concomitant Diuretic Therapy, and others

*
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies

*
Unmet Needs, KOL's views, Analyst's views, Malignant Ascites Market Access and Reimbursement

To know more about Malignant Ascites companies working in the treatment market, visit @ Malignant Ascites Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/malignant-ascites-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]

Table of Contents

*
Malignant Ascites Market Report Introduction

*
Executive Summary for Malignant Ascites

*
SWOT Analysis of Malignant Ascites

*
Malignant Ascites Patient Share (%) Overview at a Glance

*
Malignant Ascites Market Overview at a Glance

*
Malignant Ascites Background and Overview

*
Malignant Ascites Epidemiology and Patient Population

*
Country-Specific Patient Population of Malignant Ascites

*
Malignant Ascites Current Treatment and Medical Practices

*
Malignant Ascites Unmet Needs

*
Malignant Ascites Emerging Therapies

*
Malignant Ascites Market Outlook

*
Country-Wise Malignant Ascites Market Analysis (2022-2036)

*
Malignant Ascites Market Access and Reimbursement of Therapies

*
Malignant Ascites Market Drivers

*
Malignant Ascites Market Barriers

*
Malignant Ascites Appendix

*
Malignant Ascites Report Methodology

*
DelveInsight Capabilities

*
Disclaimer

*
About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=malignant-ascites-market-is-expected-to-witness-significant-growth-by-2036-owing-to-the-launch-of-novel-therapies-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/consulting/due-diligence-services
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.